Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

David S. Knopman, Joel S. Perlmutter

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

The US Food and Drug Administration (FDA) approved aducanumab on June 7, 2021, using an accelerated approval mechanism, based on evidence that aducanumab reduced brain β-amyloid (Aβ) peptide.1 The FDA press release stated that the effect on the surrogate end point "is reasonably likely to predict a clinical benefit to patients."at some point in the future. As clinical neurologists, we should understand the evidence for this approval and whether this justifies prescribing this medication.

Original languageEnglish
Pages (from-to)545-547
Number of pages3
JournalNeurology
Volume97
Issue number11
DOIs
StatePublished - Sep 14 2021

Fingerprint

Dive into the research topics of 'Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks'. Together they form a unique fingerprint.

Cite this